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ABSTRACT 
 
The overall goal of this project was to document and evaluate the new breakthrough 
technology of human therapeutic cloning which was finally achieved this year, and to assess the 
ethical problems associated it.  We performed a review of the current research literature and 
conducted interviews with academic researchers and bioethicists.  Our findings indicate that the 
use of human eggs is the most important ethical consideration in this process, and the use of eggs 
could become rate-limiting if the process is used to treat human diseases.  The problem is further 
hindered because the eggs need to be fresh and young, and because most states do not have their 
own specific laws governing egg harvesting, so we recommend that individual states consider 
changing their laws to allow for donor compensation to increase egg donations.  Because the 
epigenetic status of a cell’s DNA can affect its ability to differentiate and several labs reported 
DNA mutations in their cells, we recommend that all types of pluripotent cell lines be frequently 
monitored for DNA mutations, epigenetic modifications, differentiation potential, tumor 
potential, and ability to treat a disease, before AND after expansion for clinical safety.  The 
technology of human therapeutic cloning has advanced a long way in a very short period of time, 
and the methods are constantly improving.  We identified and recommend a best-practice 
methodology of directly fusing the enucleated egg with the diploid skin cell (to avoid loss of key 
reprogramming factors), using lower amounts of Sendai virus (to help fuse the cells) in a 
calcium-free medium, using kinase and protein translation inhibitors, and using histone de-
acetylase inhibitors, which help block early egg activation and allow the cloned human embryos 
to survive to the blastula stage (from which the therapeutic ESCs are isolated).  This best-
practice technology should be applied by all labs attempting to clone human embryos. 
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EXECUTIVE SUMMARY 
 
 
Initially proposed in 1999, human therapeutic cloning has been a major goal of the stem 
cell community for 15 years.  This process involves the transfer of a patient’s skin cell nucleus 
into an enucleated in vitro fertilized (IVF) zygote (or the direct fusion of skin cell and egg), 
culture of the zygote to the blastula stage, isolation of embryonic stem cells genetically identical 
to the patient, and the use of those cells to regrow a diseased organ in the patient.  Human 
therapeutic cloning was finally achieved in 2013 using fetal and infant skin cells, and was further 
improved in 2014 in a much broader application using adult patient skin cells.  The overall goal 
of this project was to document and evaluate this new breakthrough technology, and to assess the 
ethical problems associated it.  The specific objectives were to 1) develop a comprehensive 
assessment of the scientific experiments that lead to the development of human therapeutic 
cloning and its potential applications, 2) characterize what key scientific stakeholders believe are 
the strengths and weaknesses of the existing data and their ethical concerns, 3) evaluate the 
obtained evidence for remaining problems, and 4) recommend potential solutions to any 
remaining problems.   
To accomplish objective-1, we performed an extensive review of the current research 
literature, including reputable academic journal articles, relevant books, scholarly websites, and 
other pertinent materials.  To accomplish objective-2, we conducted a set of semi-structured, in-
depth interviews with various academic researchers in the stem cell field who have achieved 
human therapeutic cloning, or who have significantly contributed to the development of the 
cloning technology, to determine their range of opinions and the strengths and weaknesses of this 
new cloning technology.  The stakeholders included academic experts on human therapeutic 
cloning, experts on general cloning technology, scientists in biotechnology companies doing 
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therapeutic cloning, and a few bioethicists.  After performing the Literature Review and 
interviews, the group synthesized all of the information collected to ascertain the strength of the 
evidence for and against human therapeutic cloning, and created recommendations for further 
research. 
Based on the research performed for this project, our group made several conclusions and 
recommendations.  The findings are shown in more detail in the Conclusion section of the report, 
and are briefly summarized here.  With respect to the ethics of human therapeutic cloning, our 
findings indicate that the use of human eggs is the single most important ethical.  If human 
therapeutic cloning will be used in the future to treat diseases, the number of human eggs 
required will increase significantly relative to those currently used for research.  Several 
interviewees had concerns about whether a high number of eggs will be available, especially 
given that some scientists think the eggs need to be fresh and young, and given that that most 
states do not have their own specific laws governing egg harvesting.  One interviewee who 
performs human egg experiments strongly felt that donors should receive money as an incentive 
to compensate them for the surgical risk and pain of the procedure, and the inconvenience of two 
weeks of hormonal injections.  Without the compensation, the number of eggs might remain rate-
limiting.  So, we recommend that individual states consider changing their laws to allow for 
donor compensation.  Although some bioethicists tended to not respond to our inquiries, or they 
were not aware of (or were not willing to comment on) human therapeutic cloning advances, we 
compensated for this by expanding our interview selections, and by getting comments from the 
scientists directly related to ethical issues. 
With respect to using cloned nuclear transfer embryonic stem cells (NT-ESCs) versus 
induced pluripotent stem cells (iPSCs) for therapies, our research indicates that several 
researchers have directly compared the epigenetic status of the three types of pluripotent cells.  
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The epigenetic status can affect their ability to differentiate into the desired cell type, so could 
affect their usefulness for therapy.  All the scientists studying epigenetics focused on DNA 
methylation patterns, and some agreed with our recommendation that the studies should be 
expanded to include histone acetylation as another indicator of epigenetic status.  Some scientists 
concluded that NT-ESCs have an epigenetic pattern that is closer to the gold standard ESCs 
prepared by in vitro fertilization (IVF-ESCs) than iPSCs.  So, this could hinder the use of iPSCs 
in therapy, and favor the use of IVF-ESCs or NT-ESCs.  Other interviewees indicated the 
epigenetic status of the iPSCs changed to be more gold standard-like the longer they are cultured, 
so we recommend repeating this interesting finding.  Other scientists who had not yet analyzed 
epigenetics agreed with us that it is worth doing, and had plans in their own labs to do so.  
Several scientists indicated it is too early to determine which type of pluripotent stem cell is best 
in therapy until direct therapy comparisons are done.  And several interviewees identified DNA 
mutations in the pluripotent cells which they said could lead to cancer.  So, we recommend that 
all pluripotent cell lines (NT-ESCs, IVF-ESCs, iPSCs) should frequently be monitored for DNA 
mutations, epigenetic modifications, differentiation potential, tumor potential, and ability to treat 
a disease, before AND after expansion for clinical safety.  These comparisons can all be done 
now that isolating all three types of pluripotent cells is possible.  
With respect to cloning technology and its complexity, our analysis of the current 
research and our interaction with key scientists showed that the technology of human therapeutic 
cloning has advanced a long way in a very short period of time, and the methods are constantly 
improving with higher efficiencies.  One key advance is the new method of directly fusing the 
enucleated egg with the diploid skin cell, instead of microinjecting the skin cell nucleus.  
Isolating the skin cell nucleus and preparing it for microinjection likely leaves behind key 
reprogramming factors, and this is avoided by directly fusing the skin cell and egg.  This point 
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should be proven with further research.  Other recent protocol improvements included using 
lower amounts of Sendai virus (to help fuse the cells) in a calcium-free medium to prevent the 
calcium from activating the egg, using kinase and protein translation inhibitors to block early egg 
activation, and using histone de-acetylase inhibitors (to block early transcription from the 
embryo genome).  These improvements have allowed the cloned human embryos to survive to 
the blastula stage (from which the ESCs are isolated), and appear to be the best-practice 
methodology which we recommend should be applied in the future by all labs attempting to 
clone. 
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PROJECT GOALS 
 
 
Initially proposed in 1999, human therapeutic cloning has been a major goal of the stem 
cell community for 15 years.  This process involves the transfer of a patient’s skin cell nucleus 
into an enucleated in vitro fertilized (IVF) zygote (or the direct fusion of skin cell and egg), 
culture of the zygote to the blastula stage, isolation of embryonic stem cells genetically identical 
to the patient, and the use of those cells to regrow a diseased organ in the patient.  Human 
therapeutic cloning was finally achieved in 2013 using fetal and infant skin cells, and was further 
improved in 2014 in a much broader application using adult patient skin cells.  The overall goal 
of this project is to document and evaluate this breakthrough technology, and to assess the ethical 
problems associated it given the recent development of other new cell therapy alternatives that 
do not involve cloning. 
 
The specific objectives are to: 
1 Develop a comprehensive assessment of the scientific experiments that lead to the 
development of human therapeutic cloning and its potential applications. 
2 Characterize what key scientific stakeholders believe are the strengths and weaknesses 
of the existing data and their ethical concerns. 
3 Evaluate the obtained evidence for remaining problems. 
4 Recommend potential solutions to any remaining problems. 
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LITERATURE REVIEW 
 
 
 
Introduction  (Jiaxun Xie) 
This year has turned out to be a major year for human therapeutic cloning (HTC).  Within 
13 days of each other, results were published from two different labs (Chung et al., 2014; 
Yamada et al., 2014) as the first to achieve human therapeutic cloning using adult skin cell 
nuclei.  Since its original proposal in 1999 (Lanza et al., 1999), HTC represents the culmination 
of over 15 years of stem cell research, with the hope of being able to use a patient’s own skin cell 
and a donor’s egg to create an embryo from which therapeutic embryonic stem cells (ESCs) 
could be isolated that are genetically identical to the patient (so hopefully would not be rejected 
by the patient during transplant). This dream, opens the door for using a patient’s own stem cells 
for treating a variety of diseases from diabetes, to Parkinson’s disease, to spinal cord injuries, to 
metabolic disorders, and other diseases. 
But in spite of this landmark cloning discovery, some individuals are against cloning in 
general. And others argue that new procedures that do not involve cloning, such as 
reprogramming adult cells to make induced pluripotent stem cells (iPSCs), can produce ESCs 
that are as potent as cloned ESCs.  Others argue that the methods used to reprogram iPSCs 
damages their DNA or causes tumors making them unsuitable for human use.  
The purpose of this project is to document and evaluate this new technology of human 
therapeutic cloning, and to assess some of the remaining technical and ethical problems 
associated with its use. In this section we will explain what human therapeutic cloning is, and 
generally how it is done, explain the difference between reproductive cloning and therapeutic 
cloning, touch on some of the problems associated with each process, and describe what 
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embryonic stem cells are and how they are derived from the cloning process. 
 
Somatic Cell Nulear Transfer (SCNT) 
SCNT (Figure-1) is a technique for creating a viable embryo from the diploid nucleus of 
a somatic (body) cell transferred to an egg whose haploid nucleus is usually removed.  As its 
SCNT name implies, the somatic cell (usually a skin cell) nucleus is usually transferred by 
microinjection into the oocyte.  However with more recent advances, the skin cell is directly 
fused with the egg cell using Sendai virus in a process that signficantly increases embryo 
viability.   
 
 
Figure-1:  Diagram of the Cloning Process Using Somatic Cell Nuclear Transfer.  During 
SCNT, a nucleus is taken from a somatic cell (usually a skin cell) and microinjected into an 
enucleated oocyte (diagram left). The egg is then stimulated to divide, usually by using electric 
current (diagram center). If the embryo survives 5-6 days, it forms a hollow ball or blastocyst from 
which embryonic stem cells (ESCs) can be isolated to make an ESC line (diagram right). The 
derived nuclear transfer ESCs (NT-ESCs) are genetically identical to the patient providing the skin 
cell nucleus. A key recent alterations to this process includes simply fusing the oocyte and skin cell 
directly using Sendai virus instead of using microinjection. (Redrawn from Yu and Thomson, 2006) 
 
 
Human oocytes (eggs) are collected from a donor who has been previously injected with 
hormones to stimulate ovulation and the production of more than one oocyte during the 
menstrual cycle.  In the U.S., oocytes can only be harvested for reproductive purposes in a 
fertility clinic, and then later (with donor consent) the excess oocytes not used for reproduction 
can be used for research purposes. The nucleus is removed from the donated oocyte and replaced 
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with the nucleus from a somatic cell, a differentiated adult cell taken from elsewhere in the body 
(usually a skin keratinocyte). The zygote with the newly-transferred nucleus now has the same 
DNA, or genetic material, as the donor somatic cell. The embryo is simulated to divide using an 
electric current.  If the cultured embryo survives 5-6 days (only recently possible with cloned 
human embryos), it forms a blastocyst (diagram center), a hollow ball consisting of the outer 
layer of cells (the trophoblast) and the inner cell mass (ICM). Cells of the inner cell mass are 
embryonic stem cells (ESCs). ESCs isolated from cloned embryos prepared by nuclear transfer 
are sometimes abbreviated as NT-ESCs, and can in theory be used for regenerative therapies.   
 
Reproductive vs. Therapeutic Cloning 
A blastula produced by SCNT can either be implanted into the uterus of a foster mother 
in a process termed reproductive cloning, or it can be used to isolate embryonic stem cells for 
treating diseases in a process called therapeutic cloning (Figure-2). Reproductive cloning is only 
legal in the U.S. when making cloned animals and can not be applied to humans. This is also the 
case for all other countries that have bothered to legislate the cloning process. Reproductive 
cloning has been used for decades now, especially when combined with genetic engineering 
techniques, for making transgenic animals whose genomes are modified to contain a transgene 
not normally found in that organism. Transgenic animals include new disease models for 
mimicing human disease, livestock that secrete human pharmaceuticals into their milk, pigs 
whose organs are mostly histocompatible with humans for transplants, and scientific models that 
help identify the function of newly identified genes. 
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Figure-2:  Diagram of Reproductive Versus Therapeutic Cloning.  A cloned blastocyst 
(diagram center) is prepared by somatic cell nuclear transfer.  The cloned blastocyst can then 
either be implanted into the uterus of a foster mother in reproductive cloning (diagram lower right) 
or embryonic stem cells can be isolated from the blastocyst to create a therapeutic cell line in 
therapeutic cloning (diagram lower left).  (Jasper, 2013, with permission) 
 
Different than reproductive cloning, the goal of therapeutic cloning is to harvest stem 
cells that can be used to potentially treat disease, rather than creating cloned human beings. 
During therapeutic cloning, the nuclear transfer embronic stem cells (NT-ESCs) are isolated from 
the cloned blastocyst (if it has survived 5-6 days), and the NT-ESCs are cultured to make an 
immortal NT-ESC line. The goal of therapeutic cloning is to prepare a NT-ESC line that is 
genetically identical to the patient from which the skin cell was taken. These isogenic NT-ESCs, 
in theory, would not be rejected by the patient’s immune system when they are implanted into the 
16 
patient. 
Human therapeutic cloning is legal in the U.S., but has only recently been achieved: in 
2013 with fetal and infant skin cells (Tachibana et al., 2013), and in 2014 with adult skin cells 
(Chung et al., 2013; Yamada et al., 2014). Cloned ESCs have not yet been used to treat a human 
disease, however non-cloned ESCs were approved in 2010 in two different clinical trials: 1) for 
treating spinal cord injury (Geron Corporation, Menlo Park, CA) (Geron, 2014), and 2) macular 
degeneration (a specific type of blindness) (Begley, 2011; Cyranoski, 2013).  Geron stopped their 
clinical trials in 2011 when they ran out of money (Baker, 2011), but a new biotech company 
Asterias Biotherapeutics (Menlo Park, CA) is now resurrecting the spinal cord trials (Hayden, 
2014). 
 
Stem Cells 
The desired outcome of therapeutic cloning is the production of an embryonic stem cell 
line that is genetically identically to the patient. So, the topic of this IQP involves stem cells and 
we introduce it here. Within our bodies, stem cells are long lived cells that help replace aged or 
damaged tissues. These cells originate from an initial pool of stem cells formed shortly after 
fertilization (the inner cell mass of the 5-6 day old blastocyst).  Each stem cell can either divide 
to produce two more stem cells, or can differentiate to become another type of cell with a more 
specialized function. This allows stem cells to serve as an internal repair system in many tissues. 
Stem cells can sometimes undergo long periods of inactivity, but under specific physiological or 
experimental conditions, they can be induced to become mature, specialized cells that make up 
our tissues and organs. 
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Stem Cell Types 
There are three main types of stem cells: embryonic stem cells (ESCs), adult stem cells 
(ASCs), and induced pluripotent stem cells (iPSCs). ESCs are present in the inner cell mass of a 
blastocyst.  These cells are pluripotent, and can form any type of cell in the adult organism. In 
laboratories, blastocysts prepared by in vitro fertilization (IVF) procedures can be used with 
donor consent for isolating ESCs to be used for therapies. The embryos used for this purpose 
must be produced in a reproductive clinic, and only the excess embryos not used for reproduction 
can be used for research purposes. Thompson et al. (1998) were the first to isolate and grow ESC 
lines from human blastocysts, and this advance opened the door for human stem cell treatments. 
Thompson et al. grew IVF embryos in culture for 5-6 days to make a blastocyst, and then human 
embryonic stem cells were transferring cells from this pre-implantation-stage embryo into a 
plastic culture dish containing culture medium (nutrient) coated with a feeder layer of mouse 
embryonic skin cells. The mouse cells provide a scaffold for cell attachment and also release 
growth factors. After repeating the feeding for several passages, the cells that do not differentiate 
are considered ESCs. If the plated ESCs survive long term, they are continuously cultured to 
make an immortal ESC line to be used for therapy. ESC lines prepared from random IVF 
embryos are not genetically identical to a patient, while those prepared from cloned embryos are 
genetically identical to the patient who provided the donor skin cell. 
Adult stem cells (ASCs) are rare undifferentiated cells found among differentiated cells in 
a tissue or organ. The primary roles of adult stem cells in a living organism are to maintain and 
repair the tissue in which they are found. Adult stem cells are multi-potent; they can give rise to a 
few types of cells specific to the tissue they reside, but they are not pluripotent. Far more rarely, 
ASCs can trans-differentiate into cell types seen in organs or tissues other than those expected 
from the cells’ normal developmental lineage. Because they are rare, ASCs are hard to identify 
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and isolate.  Moreover, their capacity to divide is more limited than ESCs, making the generation 
of large quantities of ASCs in culture difficult.  
Induced pluripotent stem cells (iPSCs) are adult somatic cells (usually skin fibroblasts) 
reprogrammed to a pluripotent state by treating with specific transcription factors (or the genes 
encoding them). This process was first achieved in 2006 with mouse skin cells (Takahashi and 
Yamanaka, 2006) and one year later with human skin cells (Takahashi et al., 2007). Although the 
exact level of potency may vary from experiment to experiment, most scientists believe that 
iPSCs are as potent as ESCs isolated from IVF embryos. And because iPSCs can be prepared 
without cloning, some individuals believe they should be used in human therapy experiments in 
place of NT-ESCs.  However, both of these types of stem cell have problems (see below). 
 
Problems Associated with Therapeutic Cloning and iPSCs 
One of the main purposes of this IQP is to review the published literature and to 
interview scientists to help determine whether iPSCs might be able to take place of NT-ESCs in 
human therapies. The outcome of this ongoing debate will help decide in the future which types 
of cells are used for regenerative medicine to treat a variety of diseases. Our literature review 
will help us identify key problems that we should focus on for our interviews.   
With respect to cloned NT-ESCs, some individuals are against the idea of human cloning 
in any form, therapeutic or reproductive. So, these individuals are generally against the use of 
NT-ESCs because the process involves cloning. Other individuals worry about whether the 
injected NT-ESCs (or regular IVF ESCs) will form tumors at the injection site. However, 
scientists recently developed procedures for removing cancer causing cells from stem cell 
samples, including treating with antibodies against surface proteins found exclusively on cancer 
cells, or pre-differentiating the stem cells prior to injection. Other individuals worry about 
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whether we will be able to obtain enough donated human oocytes to be able to fully develop the 
technique, and whether the donors should be paid (the donation procedure is mildly painful).   
With respect to iPSCs, some cell batches have been shown to cause tumors at the 
injection site. So, as discussed above, scientists are developing procedures for identifying and 
removing the cancer causing cells from iPSC batches. Other scientists are not convinced that 
iPSCs are as potent as ESCs (or NT-ESCs), which could be a problem when treating specific 
diseases (especially if scientists cannot differentiate iPSCs as fully as ECSs). Some others argue 
that the methods used to reprogram iPSCs damages the DNA, which would be a serious problem 
as the cells are expanded for therapy. Others argue that the iPSC reprogramming does not rid the 
host DNA of its epigenetic markers (like DNA methylation or histone acetylation), and so these 
cells are not capable of full reprogramming because their DNA is altered. 
We will use our Literature Review to more fully explore the problems associated with the 
use of NT-ESCs and iPSCs, and use interviews with key stakeholders to help us evaluate the 
remaining problems to make recommendations for future research. 
 
 
Early Human SCNT Embryo Development   (Adam McNally) 
 
Although the past two years have witnessed major successes with human therapeutic 
cloning (discussed in the next section), those successes built upon an earlier body of research on 
human embryos that began in 1970’s with the advent of human in vitro fertilization (IVF).  The 
world’s first test tube baby Louise Brown was born in 1978, and the field of human embryo 
research expanded with the availability of surplus IVF embryos donated for research purposes.  
The field expanded further with the ability to grow IVF embryos to the blastocyst stage, and the 
isolation of human embryonic stem cells (ESCs) from the inner cell mass of blastocysts (Edwards, 
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2001).  The purpose of this section is to discuss some of the key human embryo experiments that 
led to the recent successes with human therapeutic cloning. 
As medicine and science advances, so do the abilities of doctors and the range of medical 
procedures possible. Surgeries involving heart, liver, lung, and pancreas transplants are now 
possible, but the need for donor organs and tissues continues to grow while the supply does not 
meet the demand. Along with the shortage of available donors, there is also the risk of immune 
incompatibility when the donors’ tissues or organs are not accepted by the patients’ immune 
system.  If human therapeutic cloning could be achieved, the tissues derived from the cloned ESCs 
would be genetically identical to the patient, so theoretically the tissues would be histo-compatible 
with the patient and not be rejected.   
The possibility of human therapeutic cloning was first discussed in 1999 by scientists at 
Advanced Cell Technology (Lanza et al., 1999).  “Advances in cloning have resulted in therapies 
with the potential to eliminate immune responses associated with the transplantation of these 
various tissues, and thus the requirement for immunosuppressive drugs that carry the risk of a wide 
variety of serious complications, including cancer, infection, renal failure, and osteoporosis” 
(Lanza et al., 1999).  Due to its potential medical applicability, the idea of human therapeutic 
cloning has come to the forefront of science.  As discussed previously, this process involves 
injecting a nucleus from a patient’s skin cell into an enucleated egg, growing the embryo to the 
blastocyst stage, isolating the ESCs, culturing the ESCs and differentiating them to the desired 
tissue, and placing those cells back into the same patient (Lanza et al., 1999).  In its earliest stages, 
our “understanding of oocyte maturation was still incomplete, and protocols for in vitro maturation 
of human embryos were unreliable and needed to be optimized” (Lanza et al., 1999).  Back in the 
early 1980’s, when the idea of therapeutic cloning was still young, scientists struggled with being 
able to grow cloned human embryos to the blastocyst stage, but this slowly improved.  And human 
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ESCs were first isolated and grown in 1998, opening the door for further experimentation 
(Thomson et al., 1998).  With breakthroughs in animal cloning using fetal and adult somatic cells 
(discussed in the previous section), the prospect of human cloning remained promising.   
In the 1990’s several studies focused on the effect of oocyte donor age and the recipient 
age on the efficiency of IVF procedures.  It was “found that the age of the oocyte donor is of 
paramount importance in predicting pregnancy outcome, while donor gravidity, parity, and the 
number of oocytes retrieved are insignificant once controlled for donor age” (Cohen et al., 1999). 
The researchers found “a positive effect of younger donor age on IVF outcome” for their SCNT 
procedures (Cohn et al., 1999). Other scientists in early cloning experiments focused on the 
developmental problems associated with cloned embryos, refining the procedures to allow better 
survival.  
 The world’s first claim of a successful human therapeutic cloning was made in 2004 by 
Woo Suk Hwang, formerly of the Seoul National University in his lab’s article entitled “Evidence 
of a pluripotent human embryonic stem cell line derived from a cloned blastocyst” (Hwang et al., 
2004).  The experiment was performed on fresh oocytes and cumulus cells donated by a healthy 
woman for the purpose of doing SCNT research. The results yielded 30 cultured SCNT-derived 
blastocysts from which 20 inner cell mass (ICM) samples were isolated by immune-surgical 
removal of the outer surrounding trophoblast layer.  Of the 20 cultured ICM samples, one produced 
a human embryonic stem cell (ESC) line (SCNT-hES-1).  The authors claimed the SCNT-hES-1 
cell line contained typical ESC surface markers, could differentiate into derivatives of all three 
main embryonic germ layers, and after continuous proliferation for more than 70 passages 
maintained normal chromosomal karyotypes (chromosome types and numbers) and were 
genetically identical to the somatic nuclear donor cells.  The authors concluded that although it 
was feasible to generate human ESCs from a somatic cell, the field needs a more reliable and 
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efficient method (Hwang et al., 2004).  Initially (prior to withdrawal of the paper for fraud), this 
first claim of SCNT in humans was considered a huge breakthrough in the field, because it “raised 
the possibility of performing human SCNT to generate potentially unlimited sources of 
undifferentiated cells for use in research, with potential applications in tissue repair and 
transplantation medicine” (Hwang et al., 2004).   
In 2005, Hwang’s lab published another paper entitled “Patient-specific embryonic stem 
cells derived from human SCNT blastocysts” (Hwang et al., 2005). In this experiment the authors 
claimed that “eleven hESC lines were established by somatic cell nuclear transfer of skin cells 
from patients with disease or injury into donated oocytes” (Hwang et al., 2005). These human 
nuclear transfer ESC lines (NT-hESCs) were established with relatively good efficiency, were 
pluripotent, chromosomally normal, matched the patient’s DNA, and appeared to match the major 
histocompatibility of the patient, which should facilitate engraftment.  However, the methods were 
still unpolished so reliability was still a lingering issue, and to be used for human therapy the SCNT 
needs to be done without the use of an animal feeder layer.  Worse, in a huge setback for the stem 
cell field, both of Hwang’s 2004 and 2005 papers were retracted in 2006 for data fabrication 
(Cyranoski, 2006). 
 In 2005, another article was published that finally produced a cloned human blastocyst, but 
not an ESC line (Stojkovic et al., 2005). This experiment was performed at the Center for Stem 
Cell Biology and Developmental Genetics at the University of Newcastle, and aimed to identify 
“the source of human oocytes with the best potential for the development to blastocysts after 
enucleation and fusion with the nucleus of a heterologous donor cell” (Stojkovic et al., 2005). Until 
then, previous studies regarding SCNT had only used fresh oocytes recovered from female 
volunteers to derive human NT embryos. This experiment compared the use of various types of 
oocytes including “oocytes that failed IVF, oocytes that were retrieved during a follicle reduction 
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procedure after ovulation induction, oocytes recovered during an IVF treatment but not 
inseminated due to unexpected azoospermia in the partner, and oocytes recovered after routine 
ovarian cystectomy” (Stojkovic et al., 2005).  Their data indicated that only the “oocytes recovered 
during a follicle reduction showed strong developmental potential after enucleation and NT”, thus 
proving that human “heterologous NT can be successfully achieved if performed in oocytes 
immediately after in vitro maturation and recovery” (Stojkovic et al., 2005).  Although the 
scientists were not able to derive ESC lines from their NT-blastocysts, this experiment laid the 
groundwork for the use of adult somatic cells as donor cells for the nucleus, and provided a better 
understanding of oocyte physiology, cell cycles, mitotic spindles, and gene expression during early 
human development. 
 In 2007, scientists at the Infertility Center at Ghent University Hospital (Belgium) 
published an article that compared three different groups of human oocytes for NT experiments: 
in vitro matured germinal vesicle oocytes (IVM), in vivo matured oocytes, and failed fertilized 
oocytes following routine intra-cytoplasmic sperm injection (ICSI) (Heindryckx et al., 2007).  
Although their success rates were highest for the in vivo matured oocytes, their study showed “for 
the first time that IVM oocytes can be used as recipients for human SCNT” (Heindryckx et al., 
2007). Of 22 treated NT-IVM oocytes, 2 human morulae were formed. 
In 2008, another relevant human SCNT experiment was the first to produce cloned 
blastocysts from adult fibroblast cell fusion, although no ESC lines were derived (French et al., 
2008).  A total of 29 oocytes were obtained by trans-vaginal aspiration from young female donors, 
were enucleated (either by extrusion or needle aspiration), and were fused with normal diploid 
adult male fibroblast cells.  The embryos developed to the pronuclear stage (66%), early cleavage 
stage (47%), or blastula stage (23%).  One cloned blastocyst was confirmed by nuclear DNA 
analysis to match the male fibroblast cell donor, and by mitochondrial DNA analysis to match the 
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oocyte donor.  This study demonstrated “for the first time, that SCNT can produce human 
blastocyst–stage embryos using cells obtained from differentiated adult cells” (French et al., 2008).  
In 2009, scientists at Advanced Cell Technology (then based on Worcester, MA) 
investigated whether animal oocytes could be used to reprogram human somatic cells (Chung et 
al., 2009). They investigated human-human, human-bovine, and human-rabbit embryos, 
comparing gene expression patterns to determine whether “human stem cells can be successfully 
generated using interspecies somatic cell nuclear transfer (iSCNT)” (Chung et al., 2009). The 
results showed that all 3 types of embryos appeared morphologically similar and they developed 
to the morula stage at the same rate, but the pattern of genomic reprogramming was dramatically 
different between the various embryos. The “bovine and rabbit oocytes do not support appropriate 
embryonic genome reprogramming of human somatic cell nuclei, and call into question the ability 
of animal ooplasm to generate patient specific human stem cells” (Chung et al., 2009). 
In addition to the technical advances of human SCNT, because the process involves human 
eggs, strong ethical issues arise.  In 2007, in response to the increasing use of human eggs for 
research, the American Society for Reproductive Medicine (ASRM) published a report from their 
ethics committee raising the question of whether human egg donors should be compensated, and 
if so, at what level (Ethics Committee, 2007).  The report details two ethical questions that financial 
compensation raises: “[1] do recruitment practices incorporating remuneration sufficiently protect 
the interests of oocyte donors, and [2] does financial compensation devalue human life by treating 
oocytes as property or commodities” (Ethics Committee, 2007).  After numerous ethical 
considerations were discussed in the report, it was concluded that a specific incentive structure 
should be put into place with regards to payment and oocyte sharing. “Monetary compensation 
should reflect the time, inconvenience, and physical and emotional demands associated with the 
oocyte donation process” (Ethics Committee, 2007).  With respect to oocyte sharing, a general 
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approach should be to “reduce the donor’s total IVF costs by about half, in exchange for a donation 
for research of half the oocytes retrieved” (Ethics Committee, 2007). 
 Another article published in 2009 also discusses ethical issues and payment regarding egg 
donors in stem cell research (Klitzman and Sauer, 2009).  The article discusses issues of donor 
exploitation from compensation, undervaluing the physical and psychological risks of donation, 
and undue inducement to donate for poor individuals. The public was surveyed on stem cell related 
questions to gain a general consensus on the public point of view.  The results indicated that women 
were most willing to donate oocytes for research when they felt they were fairly compensated. The 
report also concluded that medical care should be provided as necessary following any procedure, 
and that donor recruitment processes should be highly monitored and “the overseeing of egg 
providing must be vigilant” (Klitzman and Sauer, 2009). 
 Other key advances that helped open the door for using human ESCs in therapy were the 
development of protocols for differentiating human ESCs into specialized cells that could heal 
diseased tissues.  For example, Assady et al. (2001) developed a procedure for differentiating 
human ESCs into insulin-producing cells, while Kroon et al. (2008) were able to use those cells to 
treat a mouse model of diabetes.  And Perrier et al. (2004) were able to derive dopamine-producing 
cells from human ESCs, while Kriks et al. (2011) used the cells to treat rodent models of 
Parkinson’s disease. 
All of the above articles highlight the progress made in early human SCNT embryo 
research that helped lead to the breakthrough articles of 2013 and 2014 deriving human ESC lines 
from cloned embryos using adult patient skin cells (discussed in the next section).  Throughout the 
early years of its development, SNCT research suffered from several major obstacles that delayed 
progress, including: 1) protocol inefficiency (which necessitates using a large number of oocytes), 
2) the inability to grow the SCNT embryos to the blastocyst stage, 3) the inability to derive human 
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ESC lines from the cloned blastocysts, and 4) the inability to differentiate the derived ESC lines 
into usable tissues for therapy (Heindryckx et al., 2007).  These major hurtles appear to have finally 
been solved now.  In recognition of the large body of work on SCNT and cell reprogramming, in 
2012 John B. Gurdon (Oxford University) and Shinya Yamanaka (Kyoto University) were jointly 
awarded The 2012 Nobel Prize in Medicine or Physiology for discovering “that mature, 
specialized cells can be reprogrammed to become immature cells capable of developing into all 
tissues of the body” (Nobelprize.org, 2012).  Both men made significant contributions to cell 
reprogramming. In 1962, John B. Gurdon discovered “that the specialization of cell is reversible” 
by replacing an “immature cell nucleus in an egg cell of a frog with the nucleus from a mature 
intestinal cell” (Gurdon, 1962). In 2006, Shinya Yamanaka discovered “how intact mature cells in 
mice could be reprogrammed to become immature stem cells” (Takahashi and Yamanaka, 2006). 
These developments further came to the public eye in 2013 and 2014 with the first successful 
human therapeutic cloning using adult skin cells (discussed in the next section). 
 
 
 
Human Therapeutic Cloning of NT-ESC Lines    (Nicholas Scrivanich) 
 
 Originally proposed in 1999 (Lanza et al., 1999), human therapeutic cloning (HTC) has 
been a major goal of the stem cell community for over 15 years.  Major successes were finally 
achieved this past couple of years, opening the door to the use of therapeutic cloning to 
potentially treat patients.  The previous section of the Lit Review described some of the earliest 
human somatic cell nuclear transfer (SCNT) experiments some of which were fraudulent, and 
others achieved only short periods of embryo development.  Initially the cloned human embryos 
survived only 1-2 days, then they achieved morula status (about 3 days), and finally blastocyst 
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status (5-6 days).  But what finally opened the door for potential therapeutic use of the cells was 
the successful isolation of human embryonic stem cells (ESCs) from the cloned embryos.  In 
2013, the successes used fetal and infant donor skin cells, and in 2014 adult patient skin cells.  
The purpose of this subsection of the Lit Review is to discuss in detail these recent landmark 
cloning experiments, identifying potential problems that should be addressed in interviews for 
the IQP. 
 
Triploid Embryos 
 The world’s first “successful” human therapeutic cloning was achieved in 2011 in Dieter 
Egli’s lab at the New York Stem Cell Foundation (Noggle et al., 2011).  These scientists 
examined various ways of reprogramming somatic nuclei to a pluripotent state using human 
oocytes.  But unlike most of the previous animal experiments, they left the haploid nucleus 
inside the oocyte, creating a cloned triploid embryo when they added the diploid skin nucleus 
during SCNT.  Triploid embryos are unsuitable for human therapies, but can be used to study 
biological development.   
They started the study by finding human oocyte donors between the ages of 22-33 years 
old from the Center for Women’s Reproductive Care (CWRC) at Columbia University. After 
initially meeting the requirement for egg donation for reproductive purposes, these women 
donated their extra oocytes for research purposes.  All of the women in this study had a college 
education or better.  None of the women in the study were financially disadvantaged and they all 
had full time jobs, which lessened the ethical worries about providing financial incentives for 
egg donation. During a 19 month period, 16 out of 252 women agreed to donate their oocytes. 
These women were told what was going to happen with their oocytes by talking with their 
physician. Sixteen women donated 270 mature oocytes at meiosis stage-2 (MII) (range of 2-26, 
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and an average of 16.9 oocytes per donor cycle). Each participant was paid $8,000 for their 
donation.   
Their results showed that removing the haploid (1N) oocyte nucleus prior to 
microinjection with a diploid (2N) skin nucleus arrested the diploid embryo development at late 
cleavage stages (2-3 days), presumably due to the inability of the oocyte to activate critical 
embryonic genes from the somatic donor cell nucleus.  Thus, the removal of the oocyte nucleus 
negatively impacted the subsequent embryo’s ability to induce reprogramming.  These defects 
happened even though they used high quality young oocytes taken from women without a history 
of infertility. 
Alternatively, when the scientists left in the haploid oocyte nucleus and then 
microinjected the diploid skin nucleus to create triploid cells (1N + 2N), this allowed full 
blastocyst formation (5-6 days) and successful ES cell isolation.  The scientists concluded that 
removal of the oocyte nucleus was a critical step that prevented long-term survival of the 
embryo.  In the interview portion of our project, we hope to clarify from these scientists why 
other later experiments using diploid embryos allowed ES cell isolation with no apparent 
abnormalities. 
 
SCNT Success Using Fetal and Infant Skin Nuclei 
As mentioned above, the triploid ES cells isolated from the triploid embryos of Noggle et 
al. (2011) could not be used for human therapy.  But this setback proved moot in 2013 with the 
first production of human nuclear transfer ES cells (NT-ESCs) from diploid cloned embryos 
(Tachibana et al., 2013).  This landmark experiment was done in Shoukhrat Mitalipov’s lab at 
the Oregon National Primate Research Center using fetal and infant skin cells to provide the 
donor nuclei.  The scientists identified two key steps (a premature exit from meiosis in human 
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oocytes and a suboptimal activation) as key factors responsible for the earlier cloning failures.  
Their development of more optimal SCNT procedures allowed the production of diploid cloned 
embryos from which viable NT-ESC lines were derived.  The procedures were so efficient, the 
NT-ESC lines could be derived from as few as 2 oocytes.  Importantly, the NT-ESC lines 
showed gene expression profiles apparently equivalent to normal ESCs derived from fertilized 
embryos, and they showed normal differentiation potential, so in theory the NT-ESCs should be 
suitable for therapies (for very young patients providing the skin cells). 
Mitalipov and his team developed a protocol pieced together from several other earlier 
findings.  They used Sendai virus to efficiently unite the enucleated egg and diploid skin cells 
(using no microinjection), and gave the fused cell an electrical shock to activate development. 
After the first several attempts failed, they added caffeine to the process which protected the egg 
from premature activation.  The techniques had previous been used in different combinations 
with monkey cells, but not human cells.  The whole process including evaluating the derived 
NT-ESCs took several years because most of the time was spent navigating through US 
regulations on embryo research (Vogel, 2014). The researchers were able to prove their NT-
ESCs could widely differentiate. Their first NT-ESC line was created using fetal skin cells, the 
others were from an 8 month old patient with rare metabolic disorder Leigh syndrome. One NT-
ESC line took 15 oocytes, while another took only five, an overall efficiency that is considered 
excellent.  Tachibana et al.’s production of diploid NT-ESCs from cloned embryos in 2013 was 
considered a major innovation, and provided hope that the protocol could be later refined to 
include adult somatic cells.  Their countless hours finally paid off for these scientists with this 
huge breakthrough.  The breakthrough was extended in a spectacular way one year later in 2014 
with the production of human NT-ESCs from human cloned embryos (see below). 
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SCNT Success Using Adult Somatic Nuclei 
Some scientists worried that when using the Tachibana et al. (2013) protocol, only young 
(fetal and infant) nuclei would be suitable for reprogramming, which would not be useful for 
most adult patients.  This limiting situation changed this year with two landmark studies using 
adult skin nuclei as donors (Chung et al., 2014; Yamada et al., 2014).   
Chung and his team, in a study published in the journal Cell Stem Cell online April 15, 
2014, were able to isolate human NT-ESC lines from blastocysts cultured from human oocytes 
fused with skin cells isolated from a 35 year old male and from a 75 year old male.  Their 
procedures and culture media were similar to those described by Tachibana et al. (2013) 
(involving fusion of the oocyte with the skin cell using Sendai virus, not using nuclear 
microinjection), but included a key difference: they tested different time points of current 
application (to stimulate replication) following the viral treatment to induce fusion.  By day 6 of 
culture, the team had obtained five blastocysts: two expanded from a 30 min post-fusion 
stimulation group, and three blastocysts expanded from a 2 hour post-fusion stimulation group.  
Only those embryos derived from the 2 hour group developed to become hatching blastocysts, 
from which the scientists were able to derive stable NT-ESC lines.  The NT-ESCs could 
differentiate into several different cell types, demonstrating their feasibility for therapeutic use.  
During the interview portion of this project it will be interesting to follow up on why Chung et 
al. (2014) use of the Tachibana et al. (2013) methodology worked on adult cells here, but not for 
the original lab group.  Perhaps a key change was the waiting period of 2 hours post Sendai virus 
treatment prior to applying the electrical current to stimulate cell division. 
Thirteen days after the April 15 online release of the Chung et al. (2014) Cell Stem Cell 
paper, on April 28 another paper (Yamada et al., 2014) appeared in Nature online that 
successfully produced NT-ESCs from blastocysts cloned from somatic cells from a newborn 
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baby and from an adult 32 year old diabetic woman.  This study was performed in Dieter Egli’s 
lab at the New York Stem Cell Foundation Research Institute.  This group tested several novel 
approaches for improving the survival of cloned human blastocysts.  They used kinase and 
translation inhibitors to inhibit early activation following the use of the Sendai virus to fuse the 
egg and skin cells.  They also used histone deacetylase (HDAC) inhibitors to prevent HDACs 
from removing acetyl groups from histone proteins bound to DNA, stimulating transcription 
from the embryo DNA.  Normally, histone acetylation (by enzymes termed histone 
acetyltransferases) neutralizes the positive charges on histone proteins, decreasing their binding 
to negatively charged DNA.  Decreased histone binding converts the DNA to a more open form 
(termed euchromatin) which is transcriptionally active.  The process can be reversed using 
HDACs which help remove the acetyl groups, leaving the DNA in a condensed state (termed 
heterochromatin) which is transcriptionally inactive.  Using HDAC inhibitors (as done by the 
researchers), blocks the HDACs, so the acetyl groups remain on the histones (or are placed there 
by histone acetyltransferases) and the DNA is converted to transcriptionally active euchromatin. 
The scientists also tested several different concentrations of the Sendai virus used to fuse 
the enucleated oocyte and the diploid skin cell.  High concentrations of virus increased the 
concentration of calcium causing early activation.  So they used diluted Sendai virus in a 
calcium-free medium to prevent early activation.   
The scientists also tested the ability of the derived NT-ESCs to treat a diabetic mouse 
model.  When the NT-ESCs were differentiated into insulin-producing cells and injected into the 
diabetic mice, their blood sugar levels decreased to normoglycemia, indicating the therapy 
worked.  But it remains to be seen whether the cells would be rejected in human patients.  Their 
success deriving NT-ESCs from an adult diabetic patient is a landmark finding, and opens the 
door for using those derived ESCs to treat the same diabetic patient.  The ESCs would be 
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genetically identical to the patient, so hopefully would not be rejected by the host.  And the cells 
could be differentiated into insulin-producing pancreatic β-beta cells to treat the diabetes.  As 
stated by Susan Solomon, one of the authors on the Yamada et al. (2014) paper: 
 
“This advancement toward potential regenerative cell replacement therapies is 
significant not only for diabetes but also for many other diseases and conditions, 
including Parkinson’s, macular degeneration, multiple sclerosis, and damaged 
bones, among others. While there remain additional research hurdles to overcome 
before this work can reach the clinic, we are thrilled that our scientists have once 
again taken the lead in breaking down barriers that face the entire field.” (Farrell, 
2014). 
 
 
Some scientists think that 2014 has been an outstanding year for human SCNT 
experiments, and are excited to test the derived NT-ESCs in human therapies.  Some scientists 
think that SCNT is a better option than using iPSCs because the latter often do not become 
completely reprogramed or may become damaged during the reprogramming process, which 
could make them less stable than NT-ESCs.  Others think that iPSCs are a better way to proceed, 
worrying there will not be enough oocytes to do the therapeutic cloning process.  And should the 
oocyte donors be paid, and by whom?  These key issues will be addressed later in the report. 
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METHODS 
 
 
To accomplish objective-1, we performed an extensive review of the current research 
literature, including reputable academic journal articles, relevant books, scholarly websites, and 
other pertinent materials. 
To accomplish objective-2, we conducted a set of semi-structured, in-depth interviews 
with various academic researchers in the stem cell field who have achieved human therapeutic 
cloning, or who have significantly contributed to the development of the cloning technology, to 
determine their range of opinions on the strengths and weaknesses of this new cloning 
technology and whether other techniques that do not involve cloning could accomplish the same 
therapeutic goal. 
Who:  The stakeholders included academic experts on human therapeutic cloning, but 
also included academic experts on cloning technology in general or on potential replacements for 
cloning.  A few interviews were also conducted with scientists in biotechnology companies 
doing therapeutic cloning.  The interviewees also included academic bioethicists to help discern 
the ethical issues of human reproductive cloning.  Some of the stakeholders initially were 
identified by referral from the project advisor, Dave Adams, but the majority of subjects were 
identified from the literature as authors on key scientific papers, or by referral from the initial 
interviewees (to develop a referral “snowball”). 
Where and When:  Whenever possible, interviews were conducted in person, but the 
majority were performed by email, phone, or Skype. 
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How:  We developed our interview questions based on our background research.  A 
preliminary set of questions is shown in the Appendix.  Based on our background search of the 
interviewee and his/her responses to our initial questions, we tailored our subsequent questions to 
best obtain information from that person. The appendix shows the topics needed to fully cover 
our project. 
With respect to the method of the interview, after establishing contact with an 
interviewee, we informed the interviewee about the purpose of our project, and asked for 
permission to quote them (see interview preamble in the Appendix).  If the need arose for 
confidentiality, we protected it by either not quoting them directly, or by giving them the right to 
review any quotations used in the final published report, explaining that the interview is 
voluntary, and explaining that they may stop the interview at any time or refuse to answer any 
question.  At the end of the interview, we sometimes asked the interviewee to recommend other 
potential stakeholders we might interview, to further increase the number of interviews with key 
individuals. 
With respect to the total number of interviews performed for our project, we discontinued 
identifying new names when we had obtained sufficient information represent all sides of the 
problem, and when the unclear points had been clarified. 
To accomplish objectives-3 and 4, the group synthesized all of the information collected 
in our literature research, interviews, and follow-up interviews to ascertain the strength of the 
evidence for and against human therapeutic cloning, and created recommendations for further 
research. 
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RESULTS / FINDINGS 
 
Introduction to Three Types of Pluripotent Stem Cells, and Comparison of Therapeutic 
and Reproductive Cloning (Jiaxun Xie) 
 
The Literature Review for this section of the report focused on the process of somatic cell 
nuclear transfer (SCNT), compared the processes of reproductive cloning and therapeutic 
cloning, and provided a general background on the use of different types of pluripotent stem 
cells. The types of stem cells of direct interest to this project were cloned nuclear transfer 
embryonic stem cells (NT-ESCs) (prepared from cloned embryos), traditional ESCs (prepared 
from blastulas obtained by in vitro fertilization) (IVF-ESCs), and induced pluripotent stem cells 
(iPSCs) (prepared by reprogramming differentiated skin cells to a pluripotent state). The former 
two processes use human eggs, while the latter process does not. 
The interest of many scientists in the process of human therapeutic cloning was recently 
revived due to the recent 2014 successes published from two labs (Chung et al., 2014; Yamada et 
al., 2014) who were the first to achieve human therapeutic cloning from adult skin cell nuclei 
(discussed later in the report). The review of the literature in this area showed that some 
individuals are against the use of NT-ESCs due to the availability of iPSCs that use no eggs but 
appear to have similar differentiation potential.  Others worry that the injected NT-ESCs might 
form tumors at the injection site. Others doubt we will be able to obtain sufficient donated 
human oocytes to be able to fully develop the new technique. One of the main purposes of this 
IQP was to investigate these issues by reviewing the published literature and interviewing key 
scientists to help determine whether iPSCs might be able to take place of NT-ESCs in human 
therapies, and what experiments remain to prove this. 
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After performing the Literature Review to identify key problems in the area, we 
performed a series of interviews with several researchers that had directly performed therapeutic 
cloning or alternatively worked with iPSCs. The interviews initially focused on clarifying some 
of the ethical problems that therapeutic cloning may have, and the researchers’ attitudes towards 
the recent therapeutic cloning success, while later interviews focused on the scientists worries 
about epigenetic alterations in all 3 types of pluripotent cells. 
The first interview was performed with Dr. Robert Klitzman, a professor at the Division 
of Psychiatry, Law and Ethics, College of Physicians and Surgeons, Columbia University, New 
York State Psychiatric Institute, New York, NY 10032. Dr. Klitzman was the first author on a 
2009 article published in Reproductive BioMedicine Online, entitled “Payment of egg donors in 
stem cell research in the USA” (Klitzman and Sauer, 2009). When asked whether he would be in 
favor of using other stem cell reprogramming processes (such as iPSCs) that do not use human 
eggs if those cells are proven to be as potent as cloned cells, he validated our stance that iPSCs 
might ethically be a nice alternative to cloned ESCs, but he does not believe it is proven yet 
whether iPSCs are actually as beneficial therapeutically as IVF-ESCs. So, we concluded that 
more research needs to be done with direct therapeutic comparisons. 
The second interview was performed with Dr. Amanda A. Skillern, a scientist in the 
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San 
Francisco, CA. Dr. Skillern was the first author on a 2014 paper in Fertility and Sterility, 101: 
248-251, entitled “Oocyte Donors Comprehension as Assessed by the EDICT (Egg Donor 
Informed Consent Tool)” (Skillern et al., 2014). When asked whether donors of eggs to be used 
for research purposes should be paid, she said that she supports paying egg donors, and indeed 
her egg donors are paid (she is an MD with women donors as part of her practice). She said the 
women should be paid to be compensated for their time and for their assumption of surgical risk 
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and discomfort. And moreover, the egg simulation requires significant time out of the donor’s 
schedule, with daily appointments for ultrasounds, blood draws, and 9-12 days of daily hormone 
injections. The minor surgical procedure to retrieve eggs involves a small but real medical risk 
and is uncomfortable. Dr. Skillern also reminded us that most states currently do not allow egg 
donors to be paid, while it is important for the egg donors to get paid otherwise we will never get 
enough eggs to treat a significant number of patients. She thinks it is sad that most states do not 
allow compensation “as there is lots of good work that can be done with [human] oocytes that 
would help advance science in a number of ways”. “So the reality is that there is not going to be 
some floodgate of women willing to go through the process without compensation. There just are 
not too many people willing to inject themselves for 2 weeks, undergo a surgical procedure, and 
incur the [surgical] risk just for the good of science”. With respect to iPSCs, she said that “she 
worked in a CIRM-sponsored stem cell lab, and would be shocked if we were ever able to 
engineer a fully functional iPS cell. So, I think donated oocytes are sorely needed to continue to 
advance science”. So, she argues that some states need to change their laws to allow egg research 
and to allow donors to get paid.  
Currently, most states do not have their own specific laws governing egg harvesting, so 
they function under federal guidelines mandating IVF clinic involvement (Summary of State 
Laws and Egg Harvesting, 2014). One state (Louisiana) specifically prohibits egg donors from 
being compensated for any purpose. Five states (MA, CT, MD, CA, AZ) prohibit compensation 
for egg donors for research purposes, but are silent for egg harvesting for IVF purposes. Four 
states (RI, NJ, IL, MN) prohibit the sale of eggs obtained from human fetuses. Two states (NY, 
ID) allow for donor compensation. Although in 2013 the California legislature approved 
Assembly Bill 926 that would allow the sale of human eggs in that state, on August 13, 2013, 
Governor Jerry Brown vetoed the bill. Gov. Brown stated that, “Not everything in life is for sale, 
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nor should it be. In medical procedures of this kind, genuinely informed consent is difficult, 
because the long-term risks are not adequately known” (Donner, 2013). 
The next interview was performed with Dr. Hossam E. Fadel, a scientist and therapeutic 
cloning ethics expert at 3503 Lost Tree Lane, Augusta, Georgia 30907. Dr. Fadel was the author 
of a 2012 article published in Bioethics, 26(3): 128-135, entitled “Developments in Stem Cell 
Research and Therapeutic Cloning: Islamic Ethical Positions, A Review” (Fadel, 2012). When 
asked what he believes are the main ethical problems associated with human therapeutic cloning, 
Dr. Fadel said that ethically the two most important concerns are 1) the use of human eggs in 
general, and 2) their use for research not reproduction. Comparing the ethics of human 
therapeutic cloning versus iPSCs, he stated that because iPSCs do not use human eggs they have 
fewer ethical considerations. However, “either type of procedure should first show evidence of 
success in clinical trials, and have informed patient consent prior to proceeding”. So, Dr. Fadel 
validated the important point that the requirement for human eggs is the main ethical 
consideration when working with human therapeutic cloning, and reiterated the point seen with 
other researchers that we need more data on the use of pluripotent cells in therapies to determine 
which is best. 
The next interview was performed with Dr. Mark Tomishima, a scientist in the 
Developmental Biology Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 
10065. Dr. Tomishima was an author on a 2008 article published in Nature Medicine performing 
therapeutic cloning on Parkinson’s disease mice (Tabar et al., 2008). The researchers derived 
ESCs from mice, differentiated them into dopaminergic neurons, and then used them to treat the 
Parkinson’s model. The cloned ES cells showed efficacy and a lack of immune rejection, 
providing “proof of principle” that therapeutic cloning can work. When asked in his opinion on 
what the biggest hurdle is for using therapeutic cloning in humans, he replied: “We [first] are 
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trying to use pluripotent stem cells to treat Parkinson’s disease in non-genetically matched 
mice”. This situation would more likely mimic what will be encountered in the clinic if non-
cloned ESCs are used to treat a patient, because the IVF-ESCs would not genetically match the 
patient. He also argued that with respect to “perfect genetic matching” (therapeutic cloning), “It 
would be very hard to do that on a case-by-case basis”. So he argues that we need to continue 
researching IVF-ESCs for treating human diseases because those cells will be more readily 
available for most individual patients. 
The next interview was performed with Dr. Andrew P. Feinberg, Director of the Center 
for Epigenetics, and Professor in the Department of Medicine, Johns Hopkins University School 
of Medicine, Baltimore, MD 21205. Dr. Feinberg was one of the two corresponding authors on a 
2010 paper published in Nature, 467: 285-290, entitled “Epigenetic memory in induced 
pluripotent stem cells” (Kim et al., 2010). The authors compared the differentiation potential and 
epigenetic signature (genomic methylation patterns) of several types of pluripotent stem cells 
(including iPSCs, NT-ESCs, and IVF-ESCs) and concluded that after reprogramming to a 
pluripotent state, iPSCs retain an epigenetic signature (DNA methylation) similar to their tissue 
of origin (usually skin) especially during the early passages (before they become adapted to 
culture). When asked whether he had extended his analysis to include histone acetylation 
patterns (another type of epigenetic modification), or think it is worth doing, he replied “Clever 
of you! Yes, we have done this, but have not yet published it”. Thus, although most stem cell 
epigenetic labs are currently studying DNA methylation patterns, expanding the analysis to 
include histone acetylation patterns (another type of epigenetic modification) is also important. 
The final interview was performed with Dr. Peter J. Rugg-Gunn, a scientist at the 
Babraham Institute, Cambridge CB22 3AT, UK. Dr. Rugg-Gunn was corresponding author on a 
2007 paper published in Human Molecular Genetics, 16(2): R243-R251, entitled “Status of 
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genomic imprinting in human embryonic stem cells as revealed by a large cohort of 
independently derived and a maintained lines”. The authors analyzed 46 individual ESC lines as 
part of an International Stem Cell Initiative, and concluded that the lines were mostly 
epigenetically stable, despite differences in genetic background or method of derivation; 
however some lines showed loss of allele-specific expression. They identified several genes that 
were more variable in their methylation pattern (H19, IGF2, and MEG3) that could be used to 
provide a marker of epigenetic status. In the interview, Dr. Rugg-Gunn said he has not yet 
extended his DNA methylation marker analysis to compare cloned-ESCs with IVF-ESCs 
because human therapeutic cloning is too new. He pointed us to two 2013 and 2014 studies 
(discussed in our Literature Review), and he stated “As far as I am aware, there has not been a 
more thorough characterization of cloned-ECSs since those [2013 and 2014] studies”. 
Overall, the interviews performed for this section of the report indicate that the use of 
human eggs is the most important ethical consideration when performing human therapeutic 
cloning. One interviewee had strong concerns about obtaining a sufficient number of eggs for 
human therapeutic cloning treatments without changing specific state laws to allow egg donors 
to be paid as an incentive to compensate for their inconvenience, risk, and pain. Another 
interviewee indicated that performing human therapeutic cloning would be too hard to do on a 
case-by-case basis, so we should continue researching iPSCs that are easier to obtain. And 
several scientists indicated it is too early to determine which type of pluripotent stem cell is best 
in therapy until direct comparisons are done. With respect to stem cell comparisons, most stem 
cell labs are currently studying DNA methylation patterns, and one interviewee validated our 
opinion that we should expand the epigenetic analysis to include histone acetylation patterns, 
another type of epigenetic modification. 
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Early Human SCNT Embryo Development (Adam McNally) 
 The Literature Review for this section focused on some of the early human embryo 
experiments that eventually led to the recent 2013 and 2014 successes with human therapeutic 
cloning. Human somatic cell nuclear transfer (SCNT) experiments span both the medical and 
scientific spectra, and are a key topic in the field of regenerative medicine and stem cells.  
Cloned ESCs or nuclear transfer ESCs (NT-ESCs), in theory, are genetically identical to the 
patient, so likely they will not be rejected.  The advent of human in vitro fertilization (IVF) and 
the use of excess embryos that were donated for research when not used for reproductive 
purposes, allowed research into early human development and the production of blastocysts from 
which ESCs could be isolated.  The Literature Review on this topic revealed several successes 
and failures of human therapeutic cloning experiments.  Early experiments were not able to grow 
the embryos to the blastocyst stage, so they celebrated a simple embryo cell division or its 
survival to the morula stage (pre-blastula).  Later experiments allowed embryo survival to the 
blastula stage, isolation of ESC-lines from the blastula, and a better understanding of human 
oocyte physiology.  But the experiments also identified potential problems associated with NT-
ESCs, including DNA mutations, inefficiency of the cloning technique, and the growing 
preferred usage of induced pluripotent stem cells (iPSCs) which use no eggs but which may have 
epigenetic problems.  
To investigate these issues further, interviews were performed with several researchers 
that had early direct experience with human SCNT.  The first interview was conducted with 
Professor Miodrag Stojkovic, a scientist at the Centre for Stem Cell Biology and Developmental 
Genetics, University of Newcastle, Newcastle upon Tyne, UK.  He was the first author on the 
2005 paper in Reproductive BioMedicine Online, entitled “Derivation of a human blastocyst after 
heterologous nuclear transfer to donated oocytes” (Stojkovic et al., 2005).  His lab was the first 
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to produce a human blastocyst by SCNT, although they did not derive ESCs from the blastocyst 
for therapy. When asked what he believed was the key step leading to his success when the 
previous labs had failed, he stated that the oocytes used in the experiment had to be young and 
“fresh” in order to create human cloned embryos with a decent efficiency. However, this made it 
hard to obtain large numbers of suitable oocytes, and will continue to do so especially as human 
therapeutic cloning expands.  So, this problem may need to be solved before moving into large 
numbers of human therapy experiments.  When asked about future therapeutic cloning 
experiments, he stated that he likes the use of non-cloned cells like iPSCs for doing therapies, 
because they don’t need eggs, and that cloning “is too complicated, and too time and money 
consuming”.  Although on the other hand he argues for continued scientific research on cloning 
to better “understand which oocyte factor(s) are involved in reprogramming adult somatic and 
donor cells”. 
The second interview was performed with Dr. Andrew J. French, a scientist at the 
Stemagen Corporation, 4150 Regents Park Row, La Jolla, CA  92037.  Dr. French was the 
corresponding author on a 2008 paper published in Stem Cells, entitled “Development of Human 
Cloned Blastocysts Following Somatic Cell Nuclear Transfer (SCNT) with Adult Fibroblasts” 
(French et al., 2008). His experiment showed that cloning could create a human blastocyst; 
although he did not derive embryonic stem cells from the blastocyst to use in therapeutic cloning.  
During the interview he attributed his lab’s success to:  A) his lab’s close association with an 
IVF clinic, B) his use of pre-tested media from the IVF clinic, C) access to high quality egg 
donors, and D) quality control (half the eggs were used in their lab while the other half of the 
eggs were tested in the IVF clinics). He also remarked that a key problem remaining using NT-
ESCs for therapy is that we “don’t yet know the effectiveness of those cells for treating disease. 
But scientists’ newfound access to these cells will help alleviate this problem”.  When asked 
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about his opinion on induced pluripotent cells (iPSCs) he stated, “iPSCs are useful cell types for 
discovering stem cell treatments, but observable differences remain between iPSCs, ESCs, and 
NT-ESCs”. His belief was that ESCs, NT-ESCs, and iPSCs should all be experimented with 
because they all show different epigenetic problems, and in the end, only testing them in 
therapies will show which one is best.  
The next interviewee was Dr. Jeanne F. Loring, a Professor of Developmental 
Neurobiology, and Director of the Center for Regenerative Medicine, Department of Chemical 
Physiology, The Scripps Research Institute, La Jolla, CA 92037.  Dr. Loring was the senior 
author on a 2011 paper published in Cell Stem Cell, 8: 106-118, entitled “Dynamic changes in 
the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during 
reprogramming and time in culture” (Laurent et al., 2011).  The authors used high-resolution 
single nucleotide polymorphism (SNP) analysis of 186 pluripotent and 119 non-pluripotent stem 
cell lines.  They found a high frequency of sub-chromosomal (individual gene) copy number 
variations.  Especially interesting, they found several deletions in tumor suppressor genes and 
duplications in oncogenes, either of which could increase tumor formation.  They concluded that 
all pluripotent cell lines should frequently be monitored at the DNA level for clinical safety prior 
to use in humans.  In the interview she pointed out a recent 2014 mini-review she published in 
the Journal of Biological Chemistry on stem cell chromosome instability as related to clinical 
applications (Peterson and Loring, 2014).   In that paper, she strongly recommended using high 
SNP genotyping to monitor all stem cell batches used for human therapies, because all types of 
stem cells when cultured are known to acquire mutations over time (ESCs and iPSCs). She 
argues that they all get the same types of DNA duplications, deletions, and mutations. When 
asked about whether the gene alterations could cause cancer, she stated: “Yes, it would be great 
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if someone would do a comprehensive study on the linkage between certain common mutations 
and actual tumor genesis [so we would know what to look for prior to use in therapies]. The 
FDA has a general rule that you need to show that your cells are safe and don’t cause tumors, but 
they aren’t really pushing for anyone showing cause [specific DNA mutation) and effect 
[cancer]”. They all show mutations, but “the important issue is whether they matter.” However, 
she did assert that most of the mutations are less of a big deal than most people have suggested. 
The next interview was performed with Dr. Timo Otonkowski, a Professor of Medical 
Stem Cell Biology, Children’s Hospital and Biomedicum Stem Cell Center, University of 
Helsinki, Helsinki Fl-00014, Finland.  Dr. Otonkowski was one of the corresponding authors on 
a 2011 article published in Nature, 471: 58-62, entitled “Copy number variation and selection 
during reprogramming to pluripotency” (Hussein et al., 2011).  The authors used high-resolution 
single nucleotide polymorphism (SNP) analysis to compare iPSCs, fibroblast cells, and ESCs. 
They found several types of copy number variations between the cell types, and the more the 
iPSCs were expanded, the more ESC-like the DNA became. From the interview it was learned 
that he thinks iPSC lines should be expanded prior to use in any therapies to eliminate any 
aberrant cells present in the samples at the beginning. He also stated that “it is a great challenge 
for therapeutic applications to obtain absolute evidence for the genetic safety of these cells, since 
they occasionally gain mutations in culture that aid their adaptation to the culture environment, 
and this is true for all expanded cells”. This means that all cells grown for human therapies 
should be checked for genetic mutations prior to use in therapy, and they should be expanded to 
allow aberrant cells to be eliminated and to allow the DNA to become more ESC-like 
epigenetically.  The cells should also be monitored for DNA alteration after expansion in case 
random mutations have occurred. 
45 
 The next interview was conducted with Dr. Alexander Meissner, a scientist at the Broad 
Institute, Cambridge, MA 02142.  Dr. Meissner was one of two corresponding authors on a 2011 
paper published in Cell, 144: 439-452, entitled “Reference maps of human ES and iPS cell 
variation enable high-throughput characterization of pluripotent cell lines” (Bock et al., 
2011).  The authors indicate that substantial genetic variation has been reported for various 
pluripotent cell lines, which could affect their safety. They created genome-wide reference maps 
of DNA methylation and gene expression patterns for 20 human ESC lines and 12 iPSC lines, 
and made correlations with their ability to differentiate into more specialized cells (as would 
happen during therapy). They concluded that their assays could provide a “scorecard for quick 
and comprehensive characterization of pluripotent cell lines” (Bock et al., 2011).  During the 
interview, when asked about extending his analysis to include cloned-ESC lines, he remarked 
that it would not be necessary, because “while SCNT remains interesting, it’s no longer a likely 
method for routine generation of stem cells”.  It became clear that Dr. Meissner believes more in 
reprogrammed iPSCs (that do not use eggs) than in NT-ESCs. 
 The final interviewee was Dr. Akihiro Umezawa from the Department of Reproductive 
Biology, National Institute for Child Health and Development, Tokyo, Japan.  Dr. Umezawa is a 
corresponding author on a 2011 paper published in PLoS Genetics, 7(5), e1002085, entitled 
“DNA methylation dynamics in human induced pluripotent stem cells over time” (Nishino et al., 
2011). The authors determined the DNA methylation patterns of 22 human iPSC lines and 5 
human ESC lines, and concluded that the two cell types initially differed in their patterns, but the 
iPSCs became more ESC-like over time (the iPSCs lost their original methylation patterns 
inherited from the parental cells over time). When questioned about his work and whether he had 
analyzed NT-ESCs, Dr. Umezawa indicated that it is worth analyzing “the DNA methylation of 
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[cloned] ESC lines,” and not only has he done it, but he is in the process of submitting another 
paper on it.  “We finished it and are preparing a draft now. I hope you will also enjoy reading it 
once it gets published”. 
 Overall, the interviews performed for this portion of the project validated the preliminary 
findings of the Literature Review and brought up different opinions on using ESCs and iPSCs for 
human therapies.  Both Dr. Stojkovic and Dr. Meissner favored work with iPSCs over ESC cells 
because of the ease of reprogramming and the avoidance of human eggs, while Dr. Meissner 
went so far as to say that working with NT-ESCs is almost not even viable in the present iPSC 
environment. On the other hand, Dr. Umezawa who has recently been working exclusively on 
ESCs feels that further research on ESCs will prove most fruitful, and that ESCs have fewer 
epigenetic problems than iPSCs.  Encompassing both sides, Dr. French feels that only further 
testing will determine whether iPSCs or ESCs are better in human therapies.  Our analysis of the 
current research and our interaction with key scientists has shown that human therapeutic cloning 
has advanced a long way in a very short period of time, and the methods are constantly 
improving with higher efficiencies.  However, many avenues of research still need to be done. If 
NT-ESCs are used for human therapies in large numbers, suitable human eggs may soon become 
rate-limiting because some scientists found that only fresh and young eggs currently work in the 
cloning protocol.  And several interviewees recommended, and we agree, that all pluripotent cell 
lines (NT-ESCs, IVF-ESCs, iPSCs) should frequently be monitored for DNA mutations, 
epigenetic modifications, differentiation potential, and tumor potential, before AND after 
expansion for clinical safety.  And in the end, we do not know the effectiveness of any of these 
pluripotent cells for treating human diseases, so research should continue in all areas. 
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Human Therapeutic Cloning of ES Cell Lines    (Nicholas Scrivanich) 
 
The Literature Review performed for this section of the report showed that years 2013 
and 2014 were outstanding for human therapeutic cloning experiments.  Scientists finally 
succeeded at preparing human embryonic stem cells (hESCs) by microinjecting a skin cell 
nucleus from an adult human patient into an enucleated egg, growing the embryo in vitro to the 
blastocyst stage, and isolating the cloned ESCs from the blastocyst inner cell mass.  This process 
creates nuclear transfer ESCs (NT-ESCs) that are genetically identical to the patient, and which 
in theory can be used to treat the same patient without immune-rejection.  The NT-ESCs could 
also be prepared by simply fusing the skin cell directly with the human egg using Sendai virus to 
aid the fusion.  At the end of their landmark papers, the scientists concluded how excited they are 
to test the NT-ESCs in human therapies in the future. 
However, our review also pointed us to some potential problems of using NT-ESCs for 
therapies, including potential epigenetic modifications (DNA methylation, histone acetylation) 
that might prevent full cell reprogramming, and logistical and ethical problems associated with 
using human eggs in the procedures.  Some scientists thought that using induced pluripotent stem 
cells (iPSCs) instead of NT-ESCs might be better.  iPSCs can be prepared from adult skin cells 
by directly reprogramming them with specific genes that initiates the reprogramming process, 
and the iPSC process does not use human eggs.  Other scientists worried that iPSCs show even 
greater epigenetic problems than NT-ESCs which could hinder their use in therapies. 
 To help resolve some of these issues, we performed a series of interviews with scientists 
who have performed the NT-ESC process themselves, and who have characterized these cells.  
The first interview was performed with Dr. Shoukhrat Mitalipov of the Division of Reproductive 
and Developmental Sciences, Oregon National Primate Research Center, Oregon Health and 
Science University, 505 NW 185th Avenue, Beaverton, OR  97006.  Dr. Mitalipov is senior 
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author on a 2013 paper published in Cell (Tachibana et al., 2013) that was the first to achieve 
human therapeutic cloning without producing undesired triploid cells that earlier protocols had 
produced (triploid cells are produced when diploid nuclei are injected into non-enucleated eggs 
containing haploid nuclei).  Mitalipov’s group succeeded while using fetal and infant skin donor 
cells, but not with adult skin cells.  When asked why he was able to achieve his human 
therapeutic cloning success, Dr. Mitalipov responded that his success resulted from finally being 
able to grow the cloned embryos to the blastula stage from which the ESCs could be isolated.  
“Yes, we succeeded in human SCNT because we were able to support growth of embryos to 
blastocysts”.  And when commenting on other scientist’s worries about whether NT-ESCs can be 
used for human therapies and how robust he thinks the cells are, he stated “So far, it seems that 
human SCNT-derived stem cells are much better [than iPSCs] in terms of quality.”  So, he 
believes that we need to continue researching NT-ESCs not just iPSCs for human therapies. 
The second interview was performed with Dr. Dieter Egli of The New York Stem Cell 
Foundation Research Institute, New York, NY 10032.  Dr. Egli is senior author on a key 2014 
Nature paper (Yamada et al., 2014) that was the first to derive diploid pluripotent stem cells 
(similar to embryonic stem cells) from an adult patient with diabetes.  When asked why he was 
able to succeed when previous researchers had failed, he said that he never liked microinjecting 
the skin nucleus into the egg [which presumably leaves key reprogramming factors behind], and 
instead prefers using Sendai virus to directly fuse the egg and skin cell together.  He credited his 
recent success to three key steps not done previously that help increase human embryo survival 
to the blastocyst stage (from which the ESCs were isolated):  1) using lower amounts of Sendai 
virus than previous experiments in a calcium-free medium to prevent the calcium from activating 
the egg, 2) using kinase and protein translation inhibitors to block early egg activation, and 3) 
using histone de-acetylase inhibitors (to block early transcription from the embryo genome).  He 
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verified that their timing of egg activation with the electric current to initiate cell division was 
the same timing used in Chung et al. (2014) (2 hours post Sendai fusion).  He was not convinced 
that 30 minute activation times were really accurate.  In a follow-up interview, Dr. Egli said that 
he thought we would need BOTH cloned ESCs and iPS cells for human therapies, as it is too 
soon to know which will work best. 
The third interview was with Dr. Young Gie Chung of the Research Institute for Stem 
Cell Research, CHA Health Systems, Los Angeles, CA 90036.  Dr. Chung is first author on the 
2014 Cell Stem Cell paper (Chung et al., 2014) which was the first to show that adult dermal 
fibroblasts (from 35- and 75-year old donors) can be used to create embryonic stem cells by 
SCNT cloning.  Dr. Chung clarified that the methods allowing him to succeed with human 
therapeutic cloning from adult dermal fibroblasts were very similar to those of the earlier 2013 
Tachibana et al. paper from the Mitalipov lab that succeeded with fetal and infant donor cells.  
They used the Sendai virus envelope protein to aid cell fusion between the adult dermal 
fibroblast cell and the egg, not nuclear microinjection into the egg.  And they used electric 
current (PIEZO actuation) to activate the fused cell to begin dividing.  The only difference is 
they waited 2 hours after cell fusion before activating the eggs to begin dividing.  “Other than the 
waiting time difference, our protocol was virtually same as Dr. Mitalipov's.” 
The fourth interview was with Dr. Joseph Ecker of the Genomic Analysis Laboratory, 
The Salk Institute for Biological Sciences, La Jolla, CA 92037.  Dr. Ecker is one of three 
corresponding authors on a July 10, 2014 article published in Nature, entitled “Abnormalities in 
human pluripotent cells due to reprogramming mechanisms” (Ma et al., 2014).  The authors did a 
direct comparison of IVF embryonic stem cells (IVF-ESCs), cloned nuclear transfer ESCs (NT-
ESCs), and induced pluripotent stem cells (iPSCs) with respect to abnormalities, and concluded 
that scientists should not discontinue studying cloned NT-ESCs because they have fewer 
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epigenetic problems than iPSCs which tend to retain the epigenetic status of the original 
differentiated skin cell.  The DNA methylation pattern and transcription profile of the NT-ESCs 
looked closer to the gold standard IVF-ESCs, so they should do better in therapies, in spite of the 
fact that we would still need human eggs.  But he reminded us that this is “only molecular data, 
not functional data”.  He still has to prove the point in therapy experiments.  “Right now we have 
no data on whether they are more or less suitable for human therapies but our analysis showed 
that the epi-genome of SCNT cells is closer to ESCs (the gold standard) than are iPSCs. They 
have less reprograming and gene expression differences, so if gene expression is an indication of 
utility, then they may turn out to be more useful.  But again this has not been established, it is 
only a prediction based on molecular (not functional) evidence”. 
The fifth interview was with Dr. Louise Laurent of the Department of Reproductive 
Medicine, University of California San Diego, La Jolla, CA 92037.  Dr. Laurent is also an author 
on the Ma et al. (2014) paper along with Dr. Ecker.  She verified that our interpretation of her 
data was correct, that NT-ESCs are more faithfully reprogrammed than iPSCs, “Yes that is 
right”.  And because of that, they believe the former may be better suited for human therapies.   
Overall, the interviews from this section of the report indicate that most of the 
interviewees are concerned with the epigenetic status (DNA methylation, histone acetylation, 
etc.) of the pluripotent cells that might prevent their full reprogramming or their ability to 
differentiate into the desired cell type needed for therapy.  Some scientists thought NT-ESCs 
were more faithfully reprogrammed than iPSCs and should be used for therapies in spite of their 
use of human eggs.  Some interviewees had logistical (where to obtain large numbers of fresh 
eggs) and ethical concerns (can iPSCs replace NT-ESCs) associated with using human eggs in 
the NT-ESC procedures.  Verification was obtained on how the scientists were able to succeed 
with human therapeutic cloning.  A key ingredient appears to be the direct fusion of egg and skin 
51 
cell, instead of using only the skin cell nucleus which presumably leaves key reprogramming 
factors behind.  Other specific alterations included using lower amounts of Sendai virus than 
previous experiments in a calcium-free medium to prevent the calcium from activating the egg, 
using kinase and protein translation inhibitors to block early egg activation, and using histone de-
acetylase inhibitors (to block early transcription from the embryo genome).    
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CONCLUSIONS / RECOMMENDATIONS 
 
Based on the research performed for this project, our group is able to make several 
conclusions and recommendations.  With respect to the ethics of human therapeutic cloning, 
our findings indicate that the use of human eggs is the single most important ethical 
consideration in the entire process.  If embryonic stem cell lines obtained by therapeutic cloning 
(nuclear transfer ESCs or NT-ESCs) are used to treat human diseases, the number of human eggs 
required will increase significantly relative to those currently used for research.  Several 
interviewees had concerns about whether a high number of eggs will be available, especially 
since some scientists think the eggs need to be fresh and young, and considering the problem that 
most states do not have their own specific laws governing egg harvesting.  Only two states (NY, 
ID) currently allow for egg donor compensation, one state (Louisiana) specifically prohibits 
donor compensation for any purpose, and five states (MA, CT, MD, CA, AZ) prohibit donor 
compensation for research purposes (but are silent for egg harvesting for IVF purposes).  In 2013 
the California legislature approved Assembly Bill 926 that would allow the sale of human eggs in 
that state, but Governor Jerry Brown vetoed the bill on August 13, 2013.  One interviewee who 
performs human egg experiments strongly felt that donors should receive money as an incentive 
to compensate the donors for the surgical risk and pain of the procedure, and the inconvenience 
of two weeks of hormonal injections.  And without the compensation, the number of eggs will 
remain rate-limiting.  So, we recommend that individual states consider changing their laws to 
allow for donor compensation.   
A significant problem encountered in this project was that the bioethicists tended to not 
respond to our inquiries, or they were not aware of (or were not willing to comment on) human 
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therapeutic cloning advances.  We compensated for this by expanding our interview selections, 
and by getting comments from the scientists directly related to ethical issues. 
With respect to using NT-ESCs versus induced pluripotent stem cells (iPSCs) for 
therapies, our research indicates that several researchers have compared the epigenetic status of 
the three types of pluripotent cells.  The epigenetic status can affect their ability to differentiate 
into the desired cell type, so could affect their usefulness for therapy.  All the scientists studying 
epigenetics focused on DNA methylation patterns, and some agreed with our recommendation 
that the studies should be expanded to include histone acetylation as another indicator of 
epigenetic status.  Some scientists concluded that NT-ESCs have an epigenetic pattern that is 
closer to IVF-ESCs than iPSCs, the latter of which more closely resemble differentiated skin 
cells.  So, this could hinder the use of iPSCs in therapy, and favor the use of IVF-ESCs or NT-
ESCs.  Other interviewees indicated the epigenetic status of the iPSCs changed to be more IVF-
ESC-like the longer they are cultured, so this interesting finding is worth repeating.  Other 
scientists who had not yet analyzed epigenetics agreed with us that it is worth doing, and had 
plans in their own labs to do so.  Several scientists indicated it is too early to determine which 
type of pluripotent stem cell is best in therapy until direct therapy comparisons are done.  And 
several interviewees identified DNA mutations in the pluripotent cells which they said could lead 
to cancer.  So we recommend that all pluripotent cell lines (NT-ESCs, IVF-ESCs, iPSCs) should 
frequently be monitored for DNA mutations, epigenetic modifications, differentiation potential, 
tumor potential, and ability to treat a disease, before AND after expansion for clinical safety.  
These comparisons can all be done now that isolating all three types of pluripotent cells is 
possible.  
With respect to cloning technology and its complexity, our analysis of the current 
research and our interaction with key scientists showed that the technology of human therapeutic 
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cloning has advanced a long way in a very short period of time, and the methods are constantly 
improving with higher efficiencies.  One key advance is the new method of directly fusing the 
enucleated egg with the diploid skin cell, instead of microinjecting the skin cell nucleus as was 
originally done.  Isolating the skin cell nucleus and preparing it for microinjection likely leaves 
behind key reprogramming factors, and this is avoided by directly fusing the skin cell and egg.  
Other recent protocol improvements included using lower amounts of Sendai virus (to help fuse 
the cells) in a calcium-free medium to prevent the calcium from activating the egg, using kinase 
and protein translation inhibitors to block early egg activation, and using histone de-acetylase 
inhibitors (to block early transcription from the embryo genome).  These improvements have 
allowed the cloned human embryos to survive to the blastula stage (from which the ESCs are 
isolated), and appear to be the best-practice methodology which we recommend should be 
applied in the future by all labs attempting to clone. 
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APPENDIX   
LIST OF INTRODUCTORY INTERVIEW QUESTIONS 
Example Questions for Researchers Who Have Achieved Human Therapeutic Cloning: 
1. How strong do you think your evidence is that you have finally achieved human 
therapeutic cloning? 
2. Technically what did your lab do that allowed you to succeed in this highly competitive 
area? 
3. What experiments do you think need to be done prior to using such cells for therapy? 
4. Do you think that embryonic stem (ES) cells isolated from therapeutically cloned 
embryos are as potent as ES cells isolated from non-cloned embryos? 
5. Do you think that other types of stem cells, like induced pluripotent stem (iPS) cells, can 
serve as a replacement for ES cells isolated from cloned embryos? 
6. Do you think that iPS cells have serious problems that must be overcome prior to use in 
therapies? 
7. Do you think that the funding for therapeutic cloning experiments will increase or 
decrease? 
 
Example Questions for Academic Bio-Ethicists: 
1 Are you familiar with this year’s major discovery of the ability to perform human 
therapeutic cloning using adult patient skin cells?  If not, we will explain this briefly to 
them. 
2 What do you think are the main ethical concerns with human therapeutic cloning and the 
use of such cells for therapy? 
3 Do you think researchers should try to find alternatives for therapeutic treatments? 
4 Do you think that more research should be performed to more fully understand 
therapeutic cloning prior to using such cells for therapy? 
5 Do you think that individual state laws should be changed to allow egg donors to be 
compensated? 
 
Example Questions for General Cloning Researchers: 
1. How strong do you think the evidence is that scientists have achieved human therapeutic 
cloning with adult skin cells? 
2. What do you think were the key technical improvements that led to success? 
3. What were the main problems that prevented success? 
 
 
60 
INTERVIEW PREAMBLE 
 
We are a group of students from the Worcester Polytechnic Institute in Massachusetts, 
and for our research project we are conducting a series of interviews to investigate problems 
associated with human therapeutic cloning and the use of those cells for therapy. 
 
Your participation in this interview is completely voluntary, and you may withdraw at 
any time. During this interview, we would like to record our conversation for later analysis. We 
will also be taking notes during the interview on key points. Is this okay with you?  
 
Can we also have your permission to quote any comments or perspectives expressed 
during the interview? This information will be used for research purposes only, and we will give 
you an opportunity to review any materials we use prior to the completion of our final report, 
which will be published on-line in WPI’s archive of projects.  
 
If the subject does not agree to be quoted, we will respond as follows: “Since you would 
not like to be quoted during this interview, we will make sure your responses are anonymous.  
No names or identifying information will appear in any of the project reports or publications.” 
 
Your participation and assistance is greatly appreciated, and we thank you for taking the 
time to meet with us. If you are interested, we would be happy to provide you with a copy of our 
results at the conclusion of our study. 
 
